DK2827711T3 - App-specifikke bace-inhibitorer (asbi'er) og anvendelse deraf - Google Patents

App-specifikke bace-inhibitorer (asbi'er) og anvendelse deraf Download PDF

Info

Publication number
DK2827711T3
DK2827711T3 DK13763620.5T DK13763620T DK2827711T3 DK 2827711 T3 DK2827711 T3 DK 2827711T3 DK 13763620 T DK13763620 T DK 13763620T DK 2827711 T3 DK2827711 T3 DK 2827711T3
Authority
DK
Denmark
Prior art keywords
asbis
app
bace inhibitors
specific bace
specific
Prior art date
Application number
DK13763620.5T
Other languages
Danish (da)
English (en)
Inventor
Varghese John
Dale E Bredesen
Original Assignee
Buck Inst Res Aging
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Buck Inst Res Aging filed Critical Buck Inst Res Aging
Application granted granted Critical
Publication of DK2827711T3 publication Critical patent/DK2827711T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/24—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK13763620.5T 2012-03-19 2013-03-15 App-specifikke bace-inhibitorer (asbi'er) og anvendelse deraf DK2827711T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261612848P 2012-03-19 2012-03-19
US201261728688P 2012-11-20 2012-11-20
PCT/US2013/032481 WO2013142370A1 (en) 2012-03-19 2013-03-15 APP SPECIFIC BACE INHIBITORS (ASBIs) AND USES THEREOF

Publications (1)

Publication Number Publication Date
DK2827711T3 true DK2827711T3 (da) 2019-09-23

Family

ID=49223272

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13763620.5T DK2827711T3 (da) 2012-03-19 2013-03-15 App-specifikke bace-inhibitorer (asbi'er) og anvendelse deraf

Country Status (10)

Country Link
US (3) US10357508B2 (enExample)
EP (2) EP3607946B1 (enExample)
JP (2) JP6482458B2 (enExample)
KR (2) KR102073578B1 (enExample)
CN (2) CN106902108B (enExample)
AU (2) AU2013235422B2 (enExample)
CA (1) CA2867891C (enExample)
DK (1) DK2827711T3 (enExample)
ES (1) ES2745539T3 (enExample)
WO (1) WO2013142370A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106902108B (zh) 2012-03-19 2020-07-21 巴克老龄化研究所 App特异性bace抑制剂(asbi)及其用途
US10729777B2 (en) 2012-04-09 2020-08-04 Case Western Reserve University Compositions and methods for inhibiting the activity of LAR family phosphatases
CN104800200B (zh) * 2014-01-23 2019-04-02 上海中医药大学 高良姜素的医药用途
JP6797408B2 (ja) * 2014-11-06 2020-12-09 国立大学法人 長崎大学 新規アルツハイマー病治療薬
KR102220260B1 (ko) 2015-02-18 2021-02-25 버크 인스티튜트 포 리서치 온 에이징 스트레스-유도성 p-tau 를 낮추는 트리아졸로피리딘 및 트리아졸로피리미딘
CN106474101A (zh) * 2015-06-17 2017-03-08 海南医学院 高良姜素在治疗糖尿病脑病药物中的应用
KR101716571B1 (ko) * 2015-06-19 2017-03-15 단국대학교 천안캠퍼스 산학협력단 알츠하이머성 치매 예방 또는 치료용 약제학적 조성물
WO2017096049A1 (en) 2015-12-03 2017-06-08 The University Of North Carolina At Pembroke Materials for cathepsin b enhancement and methods of use
EP3529237A1 (en) 2016-10-18 2019-08-28 Institut National de la Sante et de la Recherche Medicale (INSERM) Natural product derivatives for inhibiting cellular necroptosis, ferroptosis and oxytosis
CA3064479A1 (en) * 2017-06-05 2018-12-13 Case Western Reserve University Compositions and methods for treating alzheimer's disease
GB2574878A (en) * 2018-06-22 2019-12-25 Biofilm Ltd Oral compositions and mucoadhesive thin films formed therefrom
CA3111512A1 (en) 2018-09-05 2020-03-12 Case Western Reserve University Methods and compositions for inducing neural plasticity
AU2020395610A1 (en) * 2019-12-06 2022-06-30 Gretals Australia Pty Ltd Neurologically active flavonoid compositions and methods of use thereof
CN111518793A (zh) * 2020-05-20 2020-08-11 谭骏 年轻人血源APPα-分泌酶在阿尔茨海默病中的应用
US20230302009A1 (en) * 2020-08-12 2023-09-28 The Cleveland Clinic Foundation Bace1 inhibitor treatment for suppressing cytokine storm
CN112730839B (zh) * 2021-01-20 2024-01-30 宁波海尔施智造有限公司 一种磁微粒化学发光法测定细胞角蛋白19片段含量的试剂盒

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
CH677886A5 (enExample) 1989-06-26 1991-07-15 Hans Georg Prof Dr Weder
US5387742A (en) 1990-06-15 1995-02-07 Scios Nova Inc. Transgenic mice displaying the amyloid-forming pathology of alzheimer's disease
DK0568575T4 (da) 1991-01-21 2010-12-20 Elan Pharm Inc Test og model for Alzheimers sygdom
DK0620849T3 (da) 1992-01-07 2003-10-20 Elan Pharm Inc Transgene dyremodeller for Alzheimer's sygdom
US5604102A (en) 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
DE69426571T2 (de) 1993-10-27 2001-08-09 Elan Pharm Inc TRANSGENE TIERE, DIE APP Allele mit der schwedischen Mutation beherbergen
US5877399A (en) 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
FR2730932B1 (fr) 1995-02-27 1997-04-04 Oreal Nanoemulsion transparente a base de lipides amphiphiles non-ioniques fluides et utilisation en cosmetique ou en dermopharmacie
EP0871720A2 (en) 1995-06-07 1998-10-21 Athena Neurosciences, Inc. Beta-secretase, antibodies to beta-secretase, and assays for detecting beta-secretase inhibition
US5744346A (en) 1995-06-07 1998-04-28 Athena Neurosciences, Inc. β-secretase
FR2742676B1 (fr) 1995-12-21 1998-02-06 Oreal Nanoemulsion transparente a base de tensioactifs silicones et utilisation en cosmetique ou en dermopharmacie
ATE548351T1 (de) * 1996-01-29 2012-03-15 Us Of America Represented By The Secretary Dept Of Health And Human Services Dihydropyridin-pyridin-, benzopyranon- und triazolochinazolin-derivate, deren herstellung und verwendung als adenosinrezeptor-antagonisten
FR2755854B1 (fr) 1996-11-15 1998-12-24 Oreal Nanoemulsion a base de lipides amphiphiles non-ioniques et cationiques et utilisations
FR2760970B1 (fr) 1997-03-18 2000-03-10 Oreal Nanoemulsions a base de lipides amphiphiles non-ioniques et de silicones aminees et utilisations
US6492377B1 (en) * 1998-06-25 2002-12-10 Boehringer Ingelheim Pharma Kg Imidazotriazolopyrimidines with adenosine-antagonistic activity
AU5002399A (en) 1998-07-17 2000-02-07 National Broach And Machine Company Full form roll finishing technique
CA2343004A1 (en) 1998-09-24 2000-03-30 Pharmacia & Upjohn Company Alzheimer's disease secretase
FR2787026B1 (fr) 1998-12-14 2001-01-12 Oreal Nanoemulsion a base d'esters mixtes d'acide gras ou d'alcool gras, d'acide carboxylique et de glyceryle, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2787027B1 (fr) 1998-12-14 2001-01-12 Oreal Nanoemulsion a base d'esters gras de sucre ou d'ethers gras de sucre et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2787325B1 (fr) 1998-12-17 2001-01-26 Oreal Nanoemulsion a base d'esters gras de sorbitan oxyethylenes ou non oxyethylenes, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2787326B1 (fr) 1998-12-17 2001-01-26 Oreal Nanoemulsion a base d'esters gras de glycerol, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2787728B1 (fr) 1998-12-23 2001-01-26 Oreal Nanoemulsion a base d'esters gras d'acide phosphorique, et ses utilisations dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
FR2787703B1 (fr) 1998-12-29 2001-01-26 Oreal Nanoemulsion a base d'ethers gras ethoxyles ou d'esters gras ethoxyles, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2788007B1 (fr) 1999-01-05 2001-02-09 Oreal Nanoemulsion a base de copolymeres blocs d'oxyde d'ethylene et d'oxyde de propylene, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2788449B1 (fr) 1999-01-14 2001-02-16 Oreal Nanoemulsion a base de citrates d'alkylether, et ses utilisations dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
FR2789076B1 (fr) 1999-02-02 2001-03-02 Synthelabo Derives de alpha-azacyclomethyl quinoleine, leur preparation et leur application en therapeutique
US7161962B1 (en) 1999-05-27 2007-01-09 Nuera Communications, Inc. Method and apparatus for coding modem signals for transmission over voice networks
US6103756A (en) * 1999-08-11 2000-08-15 Vitacost Inc. Ocular orally ingested composition for prevention and treatment of individuals
US20010047032A1 (en) 1999-12-30 2001-11-29 Castillo Gerardo M. Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases
FR2811564B1 (fr) 2000-07-13 2002-12-27 Oreal Nanoemulsion contenant des polymeres non ioniques, et ses utilisations notamment dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
AU2002241823A1 (en) 2001-01-11 2002-07-24 Eastman Chemical Company Cyclodextrin sulfonates, guest inclusion complexes, methods of making the same and related materials
FR2819427B1 (fr) 2001-01-18 2003-04-11 Oreal Nanoemulsion translucide, son procede de fabrication et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
JP2006512401A (ja) 2001-06-05 2006-04-13 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン ナノエマルジョンワクチン
UY26816A1 (es) * 2001-07-04 2003-04-30 Horacio Heinzen Una preparación liposomal de achyrocline satureioides ("marcela"), flavonoides y derivados semisintéticos, para la protección del tejido cerebral frente al dano isquémico- vascular y neurodegenerativo.
CN100544715C (zh) 2002-04-30 2009-09-30 尤尼根制药公司 作为治疗剂的包含无取代b环类黄酮和黄烷混合物的组合物
US7476393B2 (en) 2002-11-29 2009-01-13 L'oreal Process for the preparation of a cationic nanoemulsion, and cosmetic composition
AR045219A1 (es) 2003-08-08 2005-10-19 Pharmacopeia Inc Aminas ciclicas inhibidoras de base - 1 que poseen un sustiuyente heterociclico
JP4448134B2 (ja) 2003-08-08 2010-04-07 シェーリング コーポレイション ベンズアミド置換基を有する環状アミンｂａｓｅ−１阻害剤
JP2005104850A (ja) 2003-09-26 2005-04-21 Kanazawa Univ Tlo Inc アルツハイマー病の治療薬および予防薬
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
NZ547462A (en) 2003-12-15 2010-06-25 Schering Corp Heterocyclic aspartyl protease inhibitors
US7468402B2 (en) 2004-03-17 2008-12-23 Baker Hughes Incorporated Polymeric nanoemulsion as drag reducer for multiphase flow
ES2332659T3 (es) 2004-06-16 2010-02-10 Wyeth Derivados de amino-5,5-difenilimidazolona para la inhibicion de beta-secretasa.
ES2321853T3 (es) 2004-06-16 2009-06-12 Wyeth Difenilimidazopiridina e -imidazol aminas como inhibidores de b-secretasa".
KR100610562B1 (ko) 2004-06-28 2006-08-08 재단법인서울대학교산학협력재단 플라보노이드 유도체를 포함하는 급성 또는 만성 퇴행성뇌질환의 예방 또는 치료용 조성물
DE602005025363D1 (de) 2004-07-22 2011-01-27 Schering Corp Substituierte amide als inhibitoren der beta-sekretase
AR050184A1 (es) 2004-07-28 2006-10-04 Schering Corp Inhibidores macrociclicos de beta-secretasa
CN100441200C (zh) * 2004-11-26 2008-12-10 谢德隆 石杉碱甲、乙复合成分的蛇足石杉提取物及其制备方法
CN101193892A (zh) 2005-06-14 2008-06-04 先灵公司 大环杂环天冬氨酰基蛋白酶抑制剂
KR20080025079A (ko) 2005-06-14 2008-03-19 쉐링 코포레이션 아스파르틸 프로테아제 억제제
CA2609582A1 (en) 2005-06-14 2006-12-28 Schering Corporation Aspartyl protease inhibitors
ES2436795T3 (es) 2005-06-14 2014-01-07 Merck Sharp & Dohme Corp. Inhibidores heterocíclicos de aspartil proteasa, preparación y uso de los mismos
US7759354B2 (en) 2005-06-14 2010-07-20 Schering Corporation Bicyclic guanidine derivatives as asparyl protease inhibitors, compositions, and uses thereof
DE602006018456D1 (de) 2005-06-14 2011-01-05 Schering Corp Herstellung und verwendung von verbindungen als aspartylproteasehemmer
WO2006138230A2 (en) 2005-06-14 2006-12-28 Schering Corporation The preparation and use of protease inhibitors
TW200738683A (en) 2005-06-30 2007-10-16 Wyeth Corp Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation
AU2006266167A1 (en) 2005-06-30 2007-01-11 Wyeth Amino-5-(6-membered)heteroarylimidazolone compounds and the use thereof for beta-secretase modulation
TW200730523A (en) 2005-07-29 2007-08-16 Wyeth Corp Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation
WO2007038271A1 (en) 2005-09-26 2007-04-05 Wyeth Amino-5- [4- (difluoromethoxy) phenyl] -5-phenylimidazolone compounds as inhibitors of the beta-secretase (bace)
US7763606B2 (en) 2005-10-27 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7560451B2 (en) 2005-10-31 2009-07-14 Schering Corporation Aspartyl protease inhibitors
CN101460480A (zh) 2006-04-05 2009-06-17 阿斯利康(瑞典)有限公司 2-氨基嘧啶-4-酮类化合物及其用于治疗或预防Aβ相关病理的用途
EP2644600B1 (en) 2006-06-12 2017-01-11 Merck Sharp & Dohme Corp. Heterocyclic aspartyl protease inhibitors
TW200815449A (en) 2006-06-14 2008-04-01 Astrazeneca Ab Novel compounds II
TW200808796A (en) 2006-06-14 2008-02-16 Astrazeneca Ab New compounds III
TW200815443A (en) 2006-06-14 2008-04-01 Astrazeneca Ab Novel compounds I
TW200815447A (en) 2006-06-14 2008-04-01 Astrazeneca Ab Novel compounds IV
TW200815349A (en) 2006-06-22 2008-04-01 Astrazeneca Ab New compounds
WO2008011538A2 (en) 2006-07-19 2008-01-24 The Salk Institute For Biological Studies Methods of using flavonoids to enhance memory
JP2010512390A (ja) 2006-12-12 2010-04-22 シェーリング コーポレイション 三環式系を含むアスパルチルプロテアーゼ阻害剤
CA2672293A1 (en) 2006-12-12 2008-06-19 Schering Corporation Aspartyl protease inhibitors
US20090041201A1 (en) 2007-08-06 2009-02-12 Carestream Health, Inc. Alignment apparatus for imaging system
EP2360155A4 (en) 2008-10-22 2012-06-20 Shionogi & Co 2-AMINOPYRIDIN-4-ON AND 2-AMINOPYRIDINE DERIVATIVE WITH BACE1-HEMDERING EFFECT
AP2011005707A0 (en) 2008-11-11 2011-06-30 Cspc Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd Inclusion complexes of pinocembrin with cyclodextrin or its derivatives.
WO2010105253A2 (en) * 2009-03-13 2010-09-16 The Salk Institute For Biological Studies Methods and compositions for treating complications of diabetes and vascular diseases using flavones
CN101543505A (zh) 2009-04-29 2009-09-30 香港科技大学 一种预防和治疗阿尔茨海默氏症的药物及其制备方法
CN103200949B (zh) 2010-08-10 2016-10-12 香港科技大学 用于治疗神经变性疾病或神经病理性病症的组合物
CN106902108B (zh) * 2012-03-19 2020-07-21 巴克老龄化研究所 App特异性bace抑制剂(asbi)及其用途

Also Published As

Publication number Publication date
AU2013235422B2 (en) 2016-12-15
US10835546B2 (en) 2020-11-17
CN104270945B (zh) 2017-03-29
US10357508B2 (en) 2019-07-23
ES2745539T3 (es) 2020-03-02
AU2017201599B2 (en) 2018-11-08
KR102073578B1 (ko) 2020-02-05
JP2018035197A (ja) 2018-03-08
EP2827711B1 (en) 2019-06-19
KR20150002681A (ko) 2015-01-07
AU2017201599A1 (en) 2017-03-30
USRE49873E1 (en) 2024-03-19
JP6482458B2 (ja) 2019-03-13
US20190298748A1 (en) 2019-10-03
CA2867891C (en) 2021-09-14
AU2013235422A1 (en) 2014-10-02
KR20200013807A (ko) 2020-02-07
WO2013142370A1 (en) 2013-09-26
CN106902108A (zh) 2017-06-30
CN104270945A (zh) 2015-01-07
EP2827711A1 (en) 2015-01-28
CA2867891A1 (en) 2013-09-26
EP3607946A1 (en) 2020-02-12
JP2015510941A (ja) 2015-04-13
CN106902108B (zh) 2020-07-21
KR102160388B1 (ko) 2020-09-28
EP2827711A4 (en) 2016-03-23
EP3607946B1 (en) 2023-02-22
US20150306122A1 (en) 2015-10-29

Similar Documents

Publication Publication Date Title
DK2827711T3 (da) App-specifikke bace-inhibitorer (asbi'er) og anvendelse deraf
DK2906684T3 (da) T-celle-modificerende forbindelser og anvendelser deraf
DK2914291T3 (da) Anti-komplement-c1s-antistoffer og anvendelser deraf
DK2925782T3 (da) Anti-cd47-antistoffer og fremgangsmåder til anvendelse deraf
DK2854883T3 (da) Biomatrix-hydrogeler og fremgangsmåder til anvendelse deraf
DK2903600T3 (da) Virusholdig formulering og anvendelse deraf
DK3043784T3 (da) Arylethere og anvendelser deraf
DK3381917T3 (da) Imidazopyridinforbindelser og anvendelser deraf
DK2920313T3 (da) Rekombinante adenovira og anvendelse deraf
EP2872093A4 (en) DIAPER PANTS
DK2920167T3 (da) Hydrazinyl-indol-forbindelser og konjugater
DK3608325T3 (da) Polycykliske-carbamoylpyridonforbindelser og deres farmaceutiske anvendelse
BR302013001706S1 (pt) Dispositivo portátil
DK3415157T3 (da) N-acyldipeptidderivater og anvendelser deraf
HRP20182037T1 (hr) Inhibitori prmt5 i njihova uporaba
DK2968443T3 (da) Hepcidinanaloger og anvendelser deraf
DK2920149T3 (da) 3-aminocycloalkyl-forbindelser som ror-gamma-t-inhibitorer og anvendelser deraf
DK3550836T3 (da) Fremgangsmåde og anordning til afkodning
DK3003039T3 (da) Methyl/fluor-pyridinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser og fluor-pyrimidinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser
EP2872089A4 (en) CONTAINMENT TROUSERS
DK2968173T3 (da) Heterocykliske forbindelser og anvendelser deraf
DK3063144T3 (da) Antiparasitære og pesticid-isoxazolinforbindelser
DK3077467T3 (da) Sikkativsammensætning og anvendelse deraf
DK2962100T3 (da) Tuberkulosebiomarkører og anvendelser deraf
DK3030549T3 (da) Pyridazinonforbindelser og anvendelser deraf